Payment overview · 2025
General Payments
$4,759.59
66 reported records · 12 companies
Healthcare provider profile · identity verified
Miltiadis Leon, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · SAN ANGELO, TX · NPI 1558328690
Verified facts
What the public records show
CMS Open Payments records show Miltiadis Leon, MD received $4,759.59 in general payments during 2025 across 66 reported records.
Penumbra, Inc. accounted for 36.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $1,715.66 | 36.0% | 9 | 2025 |
| Veryan Medical Incorporated | Unresolved — no canonical attribution shown | $1,168.28 | 24.6% | 20 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $802.56 | 16.9% | 12 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $357.88 | 7.5% | 9 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $274.61 | 5.8% | 4 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $192.84 | 4.0% | 3 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $99.19 | 2.1% | 1 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $53.37 | 1.1% | 2 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $43.89 | 0.9% | 3 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $22.08 | 0.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.54 | 0.3% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $13.69 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,697.39 | 63 |
| Travel and Lodging | $1,062.20 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $1,712.68 | 8 | 2025 |
Source payment records
|
|||||
| BioMimics 3D Vascular Stent System Normalized: biomimics 3d vascular stent system |
Device | Veryan Medical Incorporated | $1,168.28 | 20 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $527.16 | 7 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $274.61 | 4 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $242.22 | 3 | 2025 |
Source payment records
|
|||||
| IV Other Normalized: iv other |
Device | Philips North America LLC | $161.94 | 5 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $160.14 | 2 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $133.44 | 3 | 2025 |
Source payment records
|
|||||
| RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Normalized: relay thoracic stent graft with plus delivery system |
Device | Bolton Medical Inc | $99.19 | 1 | 2025 |
Source payment records
|
|||||
| Encore Normalized: encore |
Device | Philips North America LLC | $62.50 | 1 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $53.37 | 2 | 2025 |
Source payment records
|
|||||
| Renamic Neo Normalized: renamic neo |
Device | BIOTRONIK INC. | $53.37 | 2 | 2025 |
Source payment records
|
|||||
| OPTOWIRE Normalized: optowire |
Device | CARDIVA MEDICAL, INC. | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| PRODIGY CATHETER Normalized: prodigy catheter |
Device | Imperative Care, Inc | $32.70 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| Atlas Normalized: atlas |
Device | Bard Peripheral Vascular, Inc. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $2.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 307 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 306 | 66 |
| Cilostazol | Cilostazol | 230 | 70 |
| Furosemide | Furosemide | 230 | 64 |
| Carvedilol | Carvedilol | 221 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 210 | 52 |
| Eliquis | Apixaban | 192 | 40 |
| Atorvastatin Calcium | Atorvastatin Calcium | 156 | 43 |
| Losartan Potassium | Losartan Potassium | 150 | 41 |
| Potassium Chloride | Potassium Chloride | 146 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 31 |
| Xarelto | Rivaroxaban | 99 | 26 |
| Lisinopril | Lisinopril | 93 | 30 |
| Entresto | Sacubitril/Valsartan | 58 | 11 |
| Ezetimibe | Ezetimibe | 56 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 15 |
| Atenolol | Atenolol | 46 | 12 |
| Telmisartan | Telmisartan | 45 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 44 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Spironolactone | Spironolactone | 39 | 14 |
| Clonidine Hcl | Clonidine Hcl | 32 | 12 |
| Nitroglycerin Patch | Nitroglycerin | 31 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 31 | suppressed |
| Simvastatin | Simvastatin | 28 | suppressed |
| Brilinta | Ticagrelor | 27 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 23 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 25 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Gabapentin | Gabapentin | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,759.59 · 66 records | Penumbra, Inc. | AMVIA EDGE, AURYON LASER SYSTEM 100-120 VAC, Atlas, BIOMONITOR, BioMimics 3D Vascular Stent System, CARDIVA VASCADE 6/7F VCS, CARDIVA VASCADE MVP VVCS 6-12F, DIAMONDBACK PERIPHERAL, Encore, IV Other, Indigo System, Labosys, OPTOWIRE, Optimizer, PRODIGY CATHETER, Penumbra System, RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM, Renamic Neo, SYMPHONY CATHETER | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error